3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Carcinoma, Non-Small-Cell Lung
1
BRAF V600E Mutation
1
Interventions
Cyclophosphamide
56
fludarabine
30
Methotrexate
24
blinatumomab
22
Dexamethasone
21
Cytarabine
21
Vincristine
19
venetoclax
18
Specimen Handling
16
fludarabine phosphate
15
Whole-Body Irradiation
13
Stem Cell Transplantation
12
Biopsy
12
Tacrolimus
10
Mycophenolic Acid
10
Daunorubicin
10
Thiotepa
9
Rituximab
9
Prednisone
9
Mercaptopurine
9
Melphalan
9
Immunotherapy, Adoptive
9
Magnetic Resonance Spectroscopy
8
Doxorubicin
8
pegaspargase
7
Granulocyte Colony-Stimulating Factor
7
Cyclosporine
7
olverembatinib
6
Mesna
6
Inotuzumab Ozogamicin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Cobicistat
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA